Infectious disease outbreaks, such as measles, HIV, and mpox, expose critical vulnerabilities across public health systems.

Adults aged 18 to 64 years with high-risk conditions demonstrate higher rates of RSV-related LRTD than those without these conditions.

A study of insured US patients shows that oseltamivir is the primary influenza antiviral, while inpatient use of peramivir continues to grow.

The 2025-2026 SARS-CoV-2 vaccines provided protection against ED/UC visits and hospitalizations among immunocompetent adults.

Live attenuated measles-mumps-rubella and varicella vaccines are not associated with an increased risk for multiple sclerosis disease relapse.

A meta-analysis indicates HD-IIV is superior to SD-IIV for reducing hospitalizations in adults aged 65 years and older.

For patients with axial spondyloarthritis, bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over 3 years.

Implementation of a rapid molecular pneumonia panel is associated with earlier antimicrobial optimization among critically ill patients with pneumonia.

Infections, not eosinophilic inflammation, are the primary cause of asthma exacerbations in patients receiving benralizumab.

Studies suggesting a link between COVID-19 vaccination and improved outcomes with ICIs may be driven by pandemic-era confounding and selection bias.

Many young adults lack a primary care provider and utilize urgent care clinics for nonemergency issues instead of scheduling routine checkups.

A 24-week treatment with bofanglutide for patients with type 2 diabetes showed meaningful glycemic control, weight loss, and improvements in cardiometabolic risk factors — reductions which seemed at ...